Literature DB >> 14755542

Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells.

Kanoko Kohmura1, Yoshitaka Miyakawa, Yoko Kawai, Yasuo Ikeda, Masahiro Kizaki.   

Abstract

STI571 is a specific tyrosine kinase inhibitor of Abl kinase. It was previously reported that STI571 induced hemoglobin synthesis in the chronic myelogenous leukemia (CML) cell line K562. However, its mechanisms remain unknown. In this study, we demonstrated that STI571 induced the phosphorylation of p38 mitogen-activated protein kinase (MAPK) and dephosphorylation of extracellular signal-regulated kinase (ERK) in K562 cells. In contrast, the phosphorylation of c-Jun N-terminal kinases (JNK) in K562 cells was not altered by STI571. We also found that STI571 induced all the myeloid (CD11b, CD13), megakaryocytic (CD41a, CD42), and erythroid (glycophorin-A) markers on K562 cells. A p38 MAPK-specific inhibitor, SB203580, inhibited the STI571-induced multi-lineage differentiation of K562 cells, indicating that p38 MAPK is crucial for this differentiation. In contrast, SB203580 did not overcome the inhibitory effect for proliferation of K562 cells, indicating that p38 MAPK activation by STI571 does not affect cell numbers. Among the hematopoietic transcription factors, the expression level of c-myb mRNA was clearly downregulated after incubation with STI571 in K562 cells. STI571-induced downregulation of c-myb mRNA was prevented by the pretreatment of K562 cells by SB203580. Our data provides insights into how p38 MAPK and ERK pathways are involved in STI571-induced differentiation of K562 cells. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14755542     DOI: 10.1002/jcp.10426

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  14 in total

1.  Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway.

Authors:  P P Piccaluga; M Rossi; C Agostinelli; F Ricci; A Gazzola; S Righi; F Fuligni; M A Laginestra; M Mancini; M R Sapienza; A De Renzo; P L Tazzari; D Gibellini; P Went; F Alviano; P L Zinzani; G P Bagnara; G Inghirami; C Tripodo; S A Pileri
Journal:  Leukemia       Date:  2014-01-31       Impact factor: 11.528

2.  ERK1/2 and p38 regulate trophoblasts differentiation in human term placenta.

Authors:  Georges Daoud; Marc Amyot; Eric Rassart; André Masse; Lucie Simoneau; Julie Lafond
Journal:  J Physiol       Date:  2005-05-12       Impact factor: 5.182

3.  Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2.

Authors:  Jian-Guo Ren; Pankaj Seth; Peter Everett; Clary B Clish; Vikas P Sukhatme
Journal:  PLoS One       Date:  2010-09-02       Impact factor: 3.240

4.  Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO.

Authors:  Robert Hines; Anita Boyapati; Dong-Er Zhang
Journal:  Blood Cells Mol Dis       Date:  2007-06-21       Impact factor: 3.039

5.  Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.

Authors:  Disha Dumka; Poonam Puri; Nathalie Carayol; Crystal Lumby; Harikrishnan Balachandran; Katja Schuster; Amit K Verma; Lance S Terada; Leonidas C Platanias; Simrit Parmar
Journal:  Leuk Lymphoma       Date:  2009-12

6.  Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens.

Authors:  Alice C Fan; Debabrita Deb-Basu; Mathias W Orban; Jason R Gotlib; Yasodha Natkunam; Roger O'Neill; Rose-Ann Padua; Liwen Xu; Daryl Taketa; Amy E Shirer; Shelly Beer; Ada X Yee; David W Voehringer; Dean W Felsher
Journal:  Nat Med       Date:  2009-04-12       Impact factor: 53.440

7.  GSK3 regulates the expressions of human and mouse c-Myb via different mechanisms.

Authors:  Kyoko Kitagawa; Yojiro Kotake; Yoshihiro Hiramatsu; Ning Liu; Sayuri Suzuki; Satoki Nakamura; Akira Kikuchi; Masatoshi Kitagawa
Journal:  Cell Div       Date:  2010-11-21       Impact factor: 5.130

8.  C(5) modified uracil derivatives showing antiproliferative and erythroid differentiation inducing activities on human chronic myelogenous leukemia K562 cells.

Authors:  Eleonora Brognara; Ilaria Lampronti; Giulia Breveglieri; Alessandro Accetta; Roberto Corradini; Alex Manicardi; Monica Borgatti; Alessandro Canella; Chiara Multineddu; Rosangela Marchelli; Roberto Gambari
Journal:  Eur J Pharmacol       Date:  2011-09-21       Impact factor: 4.432

9.  Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy.

Authors:  Abhalaxmi Singh; Fahima Dilnawaz; Sanjeeb Kumar Sahoo
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

10.  Cabozantinib promotes erythroid differentiation in K562 erythroleukemia cells through global changes in gene expression and JNK activation.

Authors:  Yu-Hsuan Fu; Da-Liang Ou; Yi-Ru Yang; Kuan-Wei Su; Chien-Yuan Chen; Hwei-Fan Tien; Zheng-Sheng Lai; Che-Kun James Shen; Hsiung-Fei Chien; Liang-In Lin
Journal:  Cancer Gene Ther       Date:  2021-06-11       Impact factor: 5.854

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.